Guru Ownership Trend
Guru Analysis for Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 6 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $547.48 M.
Top institutional holders include Cliff Asness and Renaissance Technologies (RenTech).
Institutional sentiment is currently Bearish. This is evidenced by a $117.64 M net outflow during the quarter.
Recent activity highlights Joel Greenblatt who increased their stake by 22.3%. Conversely, HOTCHKIS & WILEY reduced exposure by 49.2%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for Jazz Pharmaceuticals plc (JAZZ)
Major holders include Cliff Asness ($359.94 M), Renaissance Technologies (RenTech) ($135.44 M), Joel Greenblatt ($26.99 M). According to the latest reported data, 6 tracked investment managers collectively hold approximately 2.27 M shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $117.64 M, with 2 managers increasing positions and 5 managers reducing holdings.
During the most recent reporting period, 3 managers trimmed their positions, while 2 fully exited JAZZ. The total reported sell value was $166.07 M.
Yes, 0 managers opened new positions in JAZZ, and 2 increased their existing holdings. The total reported buy value was $48.44 M.